IL5 and asthma: The usefulness of miRNAs as markers of the therapeutic response to inhaled treatment in asthma has been previously explored [14]; however, the variation in miRNAs due to biological treatment has only been analyzed after benralizumab treatment [13]; it has never been addressed with anti-IL5 drugs such as mepolizumab and reslizumab.